NEW YORK (GenomeWeb News) – Qiagen said after the close of the market Thursday that it has inked a cardiac point-of-care diagnostics alliance in China with Lepu Medical Technology, a medical device firm based in Beijing.

Under the deal, Lepu will market in China Qiagen's ESEQuant Lateral Flow System with five cardiac marker tests developed by Lepu intended to diagnose acute myocardial infarction. According to Qiagen, the system will be used in emergency rooms and the tests will be able to provide an accurate diagnosis within minutes at the point of care

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.